Kura Oncology, Inc. (NasdaqGS: KURA)
Health Care · Biotechnology · US
$13.59
+9.60% today · +77.6% 1Y
Kura Oncology, Inc. (NasdaqGS: KURA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.21B and employs 260 people.
Over the last twelve months the share price has gained 77.6%, trading between 6.95 and 12.85.
Tweenvest scores Kura Oncology, Inc. across four factors: quality 61/100, value 35/100. Its strongest factor is quality.
KURA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.21B
- Revenue (TTM)
- $77.22M
- P/E
- —
- EPS
- -3.36
- Dividend yield
- —
- Beta (5Y)
- 0.38
- 52-week high
- $12.85
- 52-week low
- $6.95
- Avg volume (3M)
- —
- Shares outstanding
- 88.96M
- Employees
- 260
- Next earnings
- —
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- ISIN
- US50127T1097
- Listed since
- Sep 16, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.